Future studies should validate these findings in larger, independent cohorts and in preclinical models, incorporating longitudinal and functional approaches to explore the mechanistic and therapeutic implications of PD-1/PD-L1/PD-L2 pathway dysregulation in endometrial cancer. Here, PDCD1LG2 is linked to endometrial cancer.